⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413153 | 1.00 | — | — | |
| SCHEMBL13600571 | 1.00 | — | — | |
| SCHEMBL29525585 | 1.00 | — | — | |
| SCHEMBL29525266 | 1.00 | — | — | |
| SCHEMBL13607589 | 1.00 | — | — | |
| SCHEMBL5868615 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL10515876 | 0.80 | GBA1 (0.34) | — | |
| SCHEMBL462864 | 0.79 | — | — | |
| SCHEMBL505753 | 0.79 | — | — | |
| SCHEMBL1313595 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606561-B2 | Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2026-04-21 | — | — | US | disclosed |
| WO-2023227125-A1 | NEW FUSED-HETEROCYCLIC COMPOUND AS CDK INHIBITOR AND USE THEREOF | 杭州德睿智药科技有限公司 | 2023-11-30 | — | — | WO | disclosed |
| US-20230348475-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRAZINE COMPOUNDS AS INHIBITORS OF CDK7 | TRANSLATIONAL GENOMICS RES INST (US) | 2023-11-02 | — | — | US | disclosed |
| EP-4255909-A1 | COMPOUNDS HAVING CYCLIN-DEPENDENT KINASE(CDK)-INHIBITORY FUNCTION | Qurient Co. Ltd. (KR) | 2023-10-11 | — | — | EP | disclosed |
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2023-05-11 | — | — | US | disclosed |
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2023-05-11 | — | — | US | disclosed |
| US-11566029-B2 | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | IP2IPO INNOVATIONS LIMITED (GB) | 2023-01-31 | — | — | US | disclosed |
| WO-2022117504-A1 | COMPOUNDS HAVING CYCLIN-DEPENDENT KINASE(CDK)-INHIBITORY FUNCTION | QURIENT CO., LTD. (KR) | 2022-06-09 | — | — | WO | disclosed |
| US-20220098208-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES | QURIENT CO., LTD. (KR) | 2022-03-31 | — | — | US | disclosed |
| US-20210253583-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | IP2IPO INNOVATIONS LIMITED (GB) | 2021-08-19 | — | — | US | disclosed |
| WO-2021122745-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2021-06-24 | — | — | WO | disclosed |
| US-10927119-B2 | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | IP2IPO INNOVATIONS LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-20200055862-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | EMORY UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
| US-10414772-B2 | Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | IMPERIAL INNOVATIONS LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| EP-3107914-B1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECH LTD (GB) | 2019-01-30 | — | — | EP | disclosed |
| US-9932344-B2 | Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-04-03 | — | — | US | disclosed |
| US-9029368-B2 | 3,7-disubstituted octahydro-2H-pyrido[4,3-E][1,3]oxazin-2-one antibiotics | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-05-12 | — | — | US | disclosed |
| US-20140309218-A1 | 3,7-DISUBSTITUTED OCTAHYDRO-2H-PYRIDO[4,3-E][1,3]OXAZIN-2-ONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-10-16 | — | — | US | disclosed |
| EP-2785721-A1 | 3,7-DISUBSTITUTED OCTAHYDRO-2H-PYRIDO[4,3-E][1,3]OXAZIN-2-ONE ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013080156-A1 | 3,7-DISUBSTITUTED OCTAHYDRO-2H-PYRIDO[4,3-E][1,3]OXAZIN-2-ONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-06-06 | — | — | WO | disclosed |